白藜芦醇甙对血小板聚集功能及内钙水平的影响

为了研究白藜芦醇甙(polydatin,PD)的抗血小板聚集作用及对细胞内钙水平的影响,并探讨其抗血栓形成作用的机制,应用Bom比浊法和Grynkiewicz方法分别测定PD对兔血小板聚集功能和血小板内钙水平的影响。PD在体外显著抑制花生四烯酸(arachidonic acid,AA)和腺苷二磷酸(adenosine diplrasphate,ADP)诱导的富血小板血浆中的血小板聚集,其半数抑制浓度(medium inhibitory concentration,IC50)分别为5．13及10．0μmol／L;5、10和20mg／kg的PD静注均明显降低兔血小板聚集率,且呈明显的剂量一效应关系;PD明显减少兔洗涤血小板内钙释放及外钙内流,本实验说明PD体内、外均有明显的抗血小板聚集作用,其机制与其降低血小板内钙浓度密切相关。     

槲皮素-3-O-乙酸酯、槲皮素-3-O-丙酸酯的制备及抗血小板聚集活性北大核心CSCD

为改善槲皮素的水溶性而不降低其抗血小板聚集活性,本文以芦丁为原料,经"3'、4'、7位羟基苄基化-酸水解苷键-3位羟基酰化-加氢脱苄基"四步反应,合成出槲皮素-3-O-乙酸酯和槲皮素-3-O-丙酸酯。两种衍生物在水中的溶解度分别为243.27μg/m L和8.13μg/m L,均高于槲皮素的溶解度。两种衍生物均对二磷酸腺苷诱导的兔体外和大鼠体内血小板聚集有显著的抑制活性,体外IC50分别为94.1μmol/L和204.9μmol/L,均低于槲皮素值,体内抑聚率均高于槲皮素。实验结果表明,通过选择性酰化槲皮素的3位羟基,引入含2个或3个碳的短脂肪烃基链,能显著改善水溶性,提高抗血小板聚集活性。     

槲皮素-3-O-乙酸酯、槲皮素-3-O-丙酸酯的制备及抗血小板聚集活性

为改善槲皮素的水溶性而不降低其抗血小板聚集活性,本文以芦丁为原料,经"3'、4'、7位羟基苄基化-酸水解苷键-3位羟基酰化-加氢脱苄基"四步反应,合成出槲皮素-3-O-乙酸酯和槲皮素-3-O-丙酸酯。两种衍生物在水中的溶解度分别为243.27μg/m L和8.13μg/m L,均高于槲皮素的溶解度。两种衍生物均对二磷酸腺苷诱导的兔体外和大鼠体内血小板聚集有显著的抑制活性,体外IC50分别为94.1μmol/L和204.9μmol/L,均低于槲皮素值,体内抑聚率均高于槲皮素。实验结果表明,通过选择性酰化槲皮素的3位羟基,引入含2个或3个碳的短脂肪烃基链,能显著改善水溶性,提高抗血小板聚集活性。     

肠淋巴液引流对失血性休克大鼠红细胞流变性的影响

目的:观察肠淋巴液引流对失血性休克大鼠红细胞流变性指标以及血液黏度的作用。方法:Wistar雄性大鼠均分为假休克组、休克组(复制失血性休克模型)、引流组(复制失血性休克模型,自低血压1 h引流休克肠淋巴液)。在低血压3 h或相应时间,经腹主动脉取血,检测红细胞参数、红细胞电泳、红细胞沉降率(ESR)以及血液黏度,计算红细胞聚集指数、红细胞变形指数。结果:与假休克组比较,休克组红细胞数量、红细胞比积(HCT)、血红蛋白(Hb)、平均红细胞血红蛋白浓度(MCHC)、红细胞电泳率与迁移率、红细胞变形指数、全血黏度、全血低切与高切相对黏度和还原黏度显著降低,休克组平均红细胞体积、红细胞电泳时间、ESR、血沉方程K值与校正K值、红细胞聚集性指数、血浆黏度显著升高;引流组MCHC、红细胞电泳率与迁移率、全血黏度、全血低切与高切还原黏度均显著降低,引流组红细胞体积分布宽度(RDW-SD)显著增加。同时,引流组HCT、RDW-SD、红细胞变形指数、全血黏度、全血低切与高切相对黏度显著高于休克组;ESR、血沉方程K值与校正K值、红细胞聚集性指数、血浆黏度显著低于休克组。结论:休克肠淋巴液引流可改善失血性休克大鼠红细胞流变行为,从而改善血液流变性。     

山莨菪碱抑制内毒素诱导血小板聚集作用

大肠杆菌内毒素诱导兔体内、外血小板聚集,使血小板内cAMP水平降低。山莨菪碱能抑制内毒素诱导的血小板聚集,并提高血小板内cAMP的水平。山莨菪碱提高血小板内cAMP 的作用可为β-受体阻断剂心得舒阻断。     

大功率微波急性辐照对血液流变特性的影响

用２．４５ＧＨｚ的连续微波对大白兔在体血液和人离体血液进行急性大剂量辐照,对辐照前和辐照后的血液粘度,粘弹性,血小板聚集性,红细胞脆性进行了实验研究,实验结果表明：微波辐照后兔血的粘度和粘弹性值降低,人血的粘度在低切变率下降低,在较高的切变率下升高;兔血小板聚集功能降低,二相聚集的解聚率增大;红细胞的脆性增大。     

丹心Ⅲ号和丹心Ⅴ号对血小板聚集功能的影响

本文观察了丹心Ⅲ号和丹心Ⅴ号对血小板聚集功能的影响,实验结果：丹心Ⅲ号和丹心Ⅴ号在体外均可显著抑制ＡＤＰ和花生四烯酸诱导的人血小板聚集,其ＩＣ５０分别为１．６０５ｍｇ／ｍｌ,２．５８９ｍｇ／ｍｌ,８．４１６ｍｇ／ｍｌ和６．６０６ｍｇ／ｍｌ;在体内可抑制连续给药１０ｄ大鼠血小板对ＡＤＰ和花生四烯酸诱导的血小板聚集,但对凝血酶诱导的血小板聚集无明显抑制作用。上述结果提示丹心Ⅲ号和丹心Ⅴ号对血小板聚集功     

大功率微波急性辐照对血液流变特性的影响

用２．４５ＧＨｚ的连续微波对大白兔在体血液和人离体血液进行急性大剂量辐照,对辐照前和辐照后的血液粘度,粘弹性,血小板聚集性,红细胞脆性进行了实验研究,实验结果表明：微波辐照后兔血的粘度和粘弹性值降低,人血的粘度在低切变率下降低,在较高的切变率下升高;兔血小板聚集功能降低,二相聚集的解聚率增大;红细胞的脆性增大。     

柚皮素-7-O-乙酸酯和柚皮素-7-O-丙酸酯的制备及抗血小板聚集活性

为改善柚皮素的水溶性而不降低其抗血小板聚集活性,本文以柚皮苷为原料,经"4'位羟基苄基化-酸水解苷键-酰化-加氢脱苄基"四步反应,合成出柚皮素-7-O-乙酸酯和柚皮素-7-O-丙酸酯。两种衍生物在水中的溶解度分别为637.34±53.23μg/m L和59.74±4.81μg/m L,均高于柚皮素的溶解度。两种衍生物均对二磷酸腺苷诱导的兔体外和大鼠体内血小板聚集有显著的抑制活性,且抑聚率均高于柚皮素。实验结果表明,通过选择酰化柚皮素的7位羟基,引入含1~2个碳的短脂肪烃基链,能显著改善水溶性,提高抗血小板聚集活性。     

天麻醒脑胶囊对家兔血小板聚集和花生四烯酸诱导大鼠脑血栓形成的影响

采用比浊方法测定天麻醒脑胶囊在体内和体外对腺苷二磷酸（ADP）、花生四烯酸（arachidonic acid,AA）和血小板活化因子（platelet activating factor,PAF）诱导家兔血小板活化聚集的影响。采用从经大鼠颈内动脉注射诱发同侧大脑半球脑血栓形成方法评价天麻醒脑胶囊的抗脑血栓形成作用。天麻醒脑胶囊在体外呈浓度依赖性明显抑制从和ADP引起的血小板聚集,其半数抑制浓度（50％of inhibitory concentration,IC50）分别为1．83和3．25g/L。0．5和1g/kg的天麻醒脑胶囊于灌胃后明显抑制从诱导的家兔血小板聚集,本品1g/kg时显著阻抑ADP引起的血小板聚集。天麻醒脑胶囊在体内外对PAF诱导的血小板聚集均无明显影响。1、2g/kg天麻醒脑胶囊组的右侧与左侧脑重差值均显著减小,显著降低右脑伊文思蓝吸光度与右脑重的比值。结果提示,天麻醒脑胶囊具有较强的抗血小板和减轻脑血栓形成作用,有利于血小板聚集性增高的血栓栓塞性疾病的防治。     

Effect of salvianolic acids from Radix Salviae miltiorrhizae on regional cerebral blood flow and platelet aggregation in rats.

This study was conducted to observe the effect of salvianolic acids (SA) on regional cerebral blood flow (rCBF) in rats and on platelet aggregation in vitro and in vivo. Cerebral ischemia was produced in rats by occluding of the right middle cerebral artery, together with the right common carotid artery. rCBF was monitored by H2 clearance method with a tissue blood-flow meter. Platelet aggregation induced by collagen, ADP, and AA was measured in vitro and in vivo by platelet aggregometer. Doses of SA at 6 and 10 mg/kg body wt. (i.v.) improved rCBF in rats after ischemia, but had no obvious effect on normal rCBF. In vitro, SA inhibited significantly the platelet aggregation induced by collagen, ADP, and AA with IC50 values of 0.197, 2.22 and 3.29 x 10(3) mg/l, respectively. In vivo, doses of SA at 6 and 10 mg/kg body wt. inhibited significantly the platelet aggregation induced by collagen, and SA at 10 mg/kg body wt. inhibited remarkably platelet aggregation induced by ADP. The results suggest that SA could improve rCBF in the ischemic hemisphere and inhibit platelet aggregation in rats.     

广西眼镜蛇毒L-氨基酸氧化酶体内外抗血小板聚集实验研究

目的 研究广西眼镜蛇中提取的L-氨基酸氧化酶(L-amino acid oxidase)在人体外及家兔体内的抗血小板聚集作用.方法 用比浊法测定广西眼镜蛇毒L-氨基酸氧化酶对二磷酸腺苷(ADP)、胶原、凝血酶、花生四烯酸(AA)在人体外及家兔体内引起的血小板聚集率的影响.结果 实验中,能明显抑制二磷酸腺苷(ADP)、胶原、凝血酶、花生四烯酸(AA)引起的血小板聚集,并呈明显的正相关.结论 广西眼镜蛇毒L-氨基酸氧化酶在体内外均有较强的抗血小板聚集活性.     

Pyrazolidine derivatives: a comparative study of their effects on platelet aggregation.

Quantitative studies were carried out of the in vitro and ex vivo effects of phenylbutazone and 3-oxoalkyl substituted diphenyldioxopyrazolidines (kebuzone, tribuzone, benzopyrazone) on platelet aggregation. The specified pyrazolidine derivatives exhibited in vitro inhibitory effects on secondary platelet aggregation (induced by adrenaline and collagen), commensurable with the effects of sulfinpyrazone. The ex vivo efficacy was markedly influenced by the height of the drug level in blood and by differences in the elimination kinetics of the pyrazolidine derivatives in human organism. Inhibitory activities against primary aggregation (induced by ADP and thrombin) were found in vitro mainly in the phenyloxoalkyl derivative of diphenyldioxopyrazolidine (benzopyrazone) and its analogues. By substitution on the phenyl attached to its alkyl side chain (for example, by a halogen in the meta position), compounds were obtained which also possessed higher activities inhibiting secondary platelet aggregation.     

重组白眉蝮蛇去整合素定点突变对其生物活性的影响

RGD为存在于许多糖蛋白配体中的氨基酸序列,对整合素具有识别作用.此序列也发现于许多蛇毒去整合素分子中.采用基因克隆技术从大连产白眉蝮蛇的毒腺中克隆出的去整合素adinbitor是含73个氨基酸残基的去整合素,分子中含有12个半胱氨酸和RGD模体.实验证明,adinbitor作为去整合素的新成员,具有典型的抗ADP诱导的人血小板聚集作用和抗肿瘤血管新生作用.为了将adinbitor的这2种功能分开,采用PCR基因定点突变的方法,将其cDNA序列中RGD模体改变成KGD.重组adinbitor(KGD)在E.coli BL21得到表达,并通过His•Bind亲和层析予以纯化.实验发现,adinbitor对ADP诱导的人血小板聚集具有明显抑制作用,其IC50=85 nmol/L,明显优于adinbitor(RGD) （IC50=150 nmol/L）.然而,与adinbitor(KGD)相比,adinbitor(KGD)则丧失了对血管生成的抑制作用.结果说明,adinbitor(KGD)可作为专一的抗人血小板聚集药具有潜在的开发前景.     

Effect of etmozin on thrombocyte aggregation capacity

It was shown in in vitro experiments that etmozin at a concentration of 100 micrograms/ml significantly suppressed (by 21%) platelet aggregation induced by ADP, but it had no effect on platelet aggregation induced by arachidonic acid. In in vivo experiments etmozin was found to cause a marked suppression of tendon collagen-induced platelet aggregation in the doses 2-5 mg/kg having antiarrhythmic activity. Under suppressed platelet aggregation induced by indomethacin, the prostaglandin biosynthesis blocker etmozin displayed no antiaggregation effect. It is suggested that etmozin effects on ADP release from platelets play the main role in the mechanism of its antiaggregation action.     

Spiramine N-6,一种新的抗血小板和抗血小板-中性粒细胞相互作用的物质

Spiramine N-6属粉花秀线菊植物中提取分离的二十碳二萜生物碱。本实验采用Born,Shen和Hamburger等方法分别观察了spiramine N-6在体外和体内对兔血小板聚集功能的影响。应用荧光分光光度法测定其对血小板5-羟色胺释放反应的作用,同时评价spiramine N-6对激活的血小板与中性粒细胞之间粘附反应的影响。结果表明：spiramine N-6在体外选择性抑制血小板活化因子(PAF)诱导的血小板聚集,并呈量效关系,其IC50=26μmol／L,对花生四烯酸(AA)或腺苷二磷酸(ADP)引起的血小板聚集无明显作用;spiramine N-6静注后明显抑制PAF、AA和ADP诱导的血小板聚集。Spiramine N-6呈浓度依赖性减少AA和PAF引起血小板5-羟色胺的释放,其IC50分别为64．7和33．5μmol／L。Spiramine N-6明显阻抑激活的血小板与中性粒细胞间的粘附率,其IC50为78．6μmol／L。结果提示spiramine N-6作为二十碳二萜生物碱具有较强的抗血小板和阻抑血小板一中性粒细胞相互作用的生物活性。     

Effect of low doses of ethanol on platelet function in long-life abstainers and moderate-wine drinkers

In vitro, high concentrations of ethanol (EtOH) reduce platelet aggregation. Less is known about the effect of low EtOH doses on platelet function in a selected human population of long-life abstainers and low moderate-wine drinkers to avoid rebound effect of EtOH on platelet aggregation. Results of our experiments suggest that moderate-wine drinkers have higher levels of high density lipoprotein (HDL) than long-life abstainers while fibrinogen levels are unchanged. Furthermore, platelets obtained from these individuals do not differ in their response when stimulated by agonists such as AA and collagen. The effect of in vitro exposure of low doses of EtOH has been studied in PRP and in washed platelets. EtOH (0.1-10 mM) inhibits platelet aggregation induced by collagen at its ED50 while is ineffective when aggregation was triggered by U-46619 and by 1 microM adenosine diphosphate (ADP). 5-10 mM EtOH partially reduces the second wave of aggregation induced by 3 microM ADP. 0.1-10 mM EtOH dose-dependently lowers the aggregation induced by AA at its ED50 but it is less effective at ED75 of AA. The antiaggregating effect of EtOH on aggregation induced by AA is unchanged by inhibitor of nitric oxide synthase. In addition, 10 mM EtOH reduces thromboxane (Tx) formation. In washed platelets, 1-10 mM EtOH partially inhibits platelet aggregation induced by thrombin. In washed resting platelets, 10 mM EtOH does not change the resting [Ca++]i while significantly reduces the increase in [Ca++]i triggered by AA. The results of ex vivo experiments have demonstrated that wine increases the HDL. However, this observation may or may not influence the response of platelets to agonists. Results of our studies demonstrate that low doses of alcohol reduces platelet function.     

The flow properties of blood and their characterization by hemorheologic methods

In a number of supply disturbances the flow behaviour of blood plays an increasing role in modern therapy concepts. The present paper deals with representing factors, such as haematocrit, aggregation, deformation, which exercise an influence on the complex flow properties of blood under variable conditions. By referring to the example of deformability it is shown how and to what extent different mechanical parameters of individual erythrocytes participate in static or dynamic whole cell deformation. Starting from fundamental quality demands (sensitivity, specificity, value of prediction) to diagnostic measuring technique, haemorheological methods for determining complex flow properties, aggregation and deformation as single phenomena and mechanical properties of individual erythrocytes are presented. Selected examples of application for normal blood, cells altered in vitro or pathological changes measured ex vivo are referred to.     

Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice.

The stable prostacyclin (PGI2) analogue, iloprost, is a potent inhibitor of both tumor cell-induced platelet aggregation and of experimental metastasis in mice. To explore possible mechanisms of antimetastatic effect of iloprost, we measured the effect of this drug on both platelet aggregation and immunocompetence in the mouse. Iloprost (4 x 10(-8) M) inhibited platelet aggregation as induced by a mixture of collagen and epinephrine for at least 180 minutes of incubation, and completely reversed platelet aggregation when added during the second wave of aggregation. In addition, aggregation of platelets obtained from iloprost-treated mice (0.2 mg/kg) was completely inhibited for at least 90 minutes of incubation. Moreover, iloprost pretreatment in vivo counteracted tumor cell-induced thrombocytopenia. Thus, mouse platelets were equally sensitive to the inhibitory effect of iloprost on aggregation as platelets of other species including humans. Effects of iloprost on parameters of host immunocompetence that may influence tumor growth and metastasis formation were also evaluated. Iloprost treatment increased significantly macrophage cytostasis to tumor cells, natural killer (NK) lytic activity of spleen cells and T-cell mediated cytotoxicity ex vivo. These results suggested that the antimetastatic effect of iloprost in the mouse may be attributable to multiple mechanisms including inhibition of platelet aggregation and stimulation of certain host immune functions.     

Blood platelets and schistosome egg excretion

The eggs of helminths of the Schistosoma genus require to be extravasated in order to continue the life cycle of the parasite. The possible mode by which this takes place was investigated in a mouse model. Suppression of platelet activity in Schistosoma mansoni-infected mice by administering rabbit anti-mouse platelet serum or a selection of "antiplatelet drugs" resulted in a significant reduction of parasite egg excretion. This reduction was best achieved when antiplatelet agents were administered just before the onset of parasite egg excretion. The association between parasite eggs and platelets was illustrated in vivo and in vitro where platelet aggregates on egg surfaces were seen in both light and electron microscopy. In addition, eggs that had been isolated from infected mouse tissues induced platelet aggregation in whole mouse blood, and this was inhibited by preincubation with the beta-lactam antibiotic, ticarcillin. Isolated eggs were also capable of inducing ex vivo platelet aggregation in mice, which was dependent on presensitization with eggs. These data suggest a role for platelets in the extravasation and excretion of parasite eggs in schistosomiasis.